

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com

June 11, 2014

Bombay Stock Exchange Limited

1st Floor, P.J. Towers

Dalal Street

MUMBAI – 400 001

Attention: Mr. Sanjay Golecha

Mr. Gopalkrishnan

Fax No. 022 – 22722039 / 3121

National Stock Exchange of India Ltd.

Exchange Plaza, 5th Floor,

Plot No. C/1, G Block

Bandra- Kurla Complex

Bandra – (East)

Mumbai – 400 051

Attention: Famroze Pochara

Asst. Vice President

Fax No. 022 – 26598237/38

Ahmedabad Stock Exchange Limited

Kamdhenu Complex

Opp. Sahajanand College

Panjra Pole,

Ahmedabad – 380 015

Fax No. 079 - 26308877

Re.: Press Release

Dear Sir / Madam


We enclose herewith a copy of press release dated June 11, 2014 regarding finalization of previously announced agreement with Warner Chilcoat Company LLC, a subsidiary of Actavis plc by the Company and Zydus Pharmaceuticals (USA), a subsidiary of the Company, to settle all outstanding patent litigation related to Asacol[®] HD (mesalamine) delayed-release tablets, to be released in the News Papers.

Please bring the aforesaid news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,

FOR CADILA HEALTHCARE LIMITED



UPEN H. SHAH

COMPANY SECRETARY

Encl.: As above.

Press Release*Ahmedabad, June 11, 2014*

Cadila Healthcare Limited, a global pharmaceuticals company, and Zydus Pharmaceuticals (USA), Inc., a leading generic pharmaceutical company in the United States, today announced that they have finalized their previously announced agreement with Warner Chilcott Company LLC, a subsidiary of Actavis plc to settle all outstanding patent litigation related to Asacol[®] HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.

Under the terms of the agreement, Warner Chilcott grants Zydus a royalty bearing license to market its generic version of Asacol[®] HD beginning on November 15, 2015 or earlier under certain circumstances, following receipt by Zydus of final approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for generic Asacol[®] HD.

Alternatively, if Zydus does not receive FDA approval of its generic Asacol[®] HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Warner Chilcott Company's product beginning on July 1, 2016. Other terms of the settlement were not disclosed.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs 16,000 people worldwide and is dedicated to creating healthier communities globally. Zydus Cadila is the only Indian pharma company to launch its own patented NCE – Lipaglyn[™], the world's first drug to be approved for the treatment of diabetic dyslipidemia. Zydus aspires to be a research-based pharmaceutical company by 2020.